During myocardial ischemia and reperfusion, nitric oxide ( ⅐ NO) was shown to exert either beneficial or detrimental effects. Uncoupled ⅐ NO synthases (NOS) can generate superoxide anion under suboptimal concentrations of substrate and cofactors. The aim of our study was to investigate the role of NOS modulation on 1) the evolution of functional parameters and 2) the amount of free radicals released during an ischemia-reperfusion sequence. Isolated perfused rat hearts underwent 30 min of total ischemia, followed by 30 min of reperfusion in the presence of N G -nitro-D-or L-arginine methyl ester (NAME, 100 M) or of D-or L-arginine (3 mM). Functional parameters were recorded and coronary effluents were analyzed with electron spin resonance to identify and quantify the amount of ␣-phenyl-N-tert-butylnitrone spin adducts produced during reperfusion.
Free radical production and calcium overload are considered as the two major events implicated in the development of myocardial ischemia and reperfusion injury (Hearse and Bolli, 1992; Maxwell and Lip, 1997; Piper et al., 1998) . The oxidative stress consecutive to an imbalance between the production of radical species and the protection by several antioxidant systems can lead to electrophysiological, biochemical, and mechanical disturbances, dramatically impairing the ability of the heart to recover from the initial ischemic insult (Hearse and Tosaki, 1987; Bolli, 1991) . Among the possible mechanisms that are supposed to be implicated in this postischemic oxidative burst, the uncoupling of mitochondrial respiratory chain (Turrens, 1997) and the activation of enzymes such as xanthine oxidase (Sobey et al., 1992) or NADPH oxidase (Griendling and Ushio-Fukai, 1997 ) have been successfully investigated. However, the interactions between free radical species (e.g., superoxide anion, hydroxyl radical, and nitric oxide) are more difficult to understand in this specific situation.
Nitric oxide ( ⅐ NO) is a gaseous nitrogen-centered free radical, released from L-arginine and dioxygen by nitric-oxide synthases (NOSs). At least three different isoforms of NOS have been identified to date. The catalytic scheme is shared by the different isoforms of NOS; however, uncoupled electron transfers have been described in NOS I (Heinzel et al., 1992; Pou et al., 1992) , II (Xia and Zweier, 1997) , and III (Vasquez-Vivar et al., 1998; Xia et al., 1998) under conditions of low concentrations of L-arginine and/or tetrahydrobiopterin, with oxygen being the acceptor of the electrons, giving rise to the superoxide anion (O 2 . ). Therefore, uncoupled electron transfer in NOS sometimes leads to the generation of a mixture of ⅐ NO and O 2 . , species that can then react with each other at a near diffusion limited rate (6.7 ϫ 10 9 M Ϫ1 ⅐ s Ϫ1 ) to produce the peroxynitrite anion (ONOO Ϫ ), which is considered as a very reactive and toxic molecule (for review, see Beckman and Koppenol, 1996) . All three isoforms of NOS may be expressed in the heart (for review, see Shah and MacCarthy, 2000) , albeit in a cell-specific manner, and the numerous physiological effects of ⅐ NO on cardiac function have been reviewed (Kelly et al., 1996) . During myocardial reperfusion, the role of ⅐ NO in the development of myocardial injury has been extensively studied in different experimental models, using either NOS antagonists (Depré et al., 1995; Naseem et al., 1995; Zweier et al., 1995; Wang and Zweier, 1996; Brunner et al., 1997; du Toit et al., 1998; Zhang et al., 2001) , L-arginine (Takeuchi et al., 1995; Engelman et al., 1996; Brunner et al., 1997; Wang et al., 1997; Mizuno et al., 1998) , ⅐ NO donors (Brunner et al., 1997; du Toit et al., 1998) , or NOS-knockout mice models (Flögel et al., 1999; Kanno et al., 2000) . However, there are contradictory results concerning the possible protective or deleterious role of ⅐ NO during ischemia and reperfusion. If ⅐ NO is a free radical, its reactivity as a radical species is low and the toxicity of ⅐ NO is likely to result from its reaction with O 2
. to produce peroxynitrite. In situations where an increase in ⅐ NO occurs at the same time as an increase in oxygen radical species production, such as during myocardial reperfusion, this may be deleterious because of the increased formation of ONOO Ϫ . On the other hand, its role as a sink for superoxide may preserve the cellular environment from hydrogen peroxide/Fenton-driven oxidative reactions. The implication of NOS activity as a modulator of oxidative stress during cardiac ischemia and reperfusion is hence conflicting and deserves more thorough investigation.
Therefore, the aim of our study was to investigate the role of NOS modulation on 1) the evolution of functional parameters and the level of postischemic recovery and 2) the amount of free radical species released during a sequence of global myocardial ischemia and reperfusion, using L-arginine as a substrate or N G -nitro-L-arginine methyl ester (L-NAME) as an inhibitor, in comparison with their D-specific enantiomers.
Materials and Methods
Chemicals. The spin trap ␣-phenyl-N-tert-butylnitrone (PBN; Sigma, Saint Quentin Fallaner, France) was purified by sublimation under argon gas and stocked at Ϫ80°C in dark vials. Toluene (highperformance liquid chromatography grade) was purchased from Fluka (Saint Quentin Fallaner, France). All other chemicals were purchased from Sigma.
Perfusion Technique and Perfusion Medium. The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH Publication 85-23, revised 1996) . Male Wistar rats (307 Ϯ 2 g) were purchased at Depré (Saint Doulchard, France). The rats were anesthetized with sodium thiopental (60 mg/kg i.p.) and heparin was intravenously injected (500 IU/kg). After 1 min, the hearts were excised and placed in a cold (4°C) perfusion buffer bath until contractions ceased. Each heart was then immediately cannulated through the aorta and perfused by the Langendorff method, at a constant perfusion pressure equivalent to 80 cm of water (8 kPa). The perfusion buffer consisted of a modified Krebs-Henseleit bicarbonate buffer (118 mM NaCl, 25 mM NaHCO 3 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 4.7 mM KCl, 5.5 mM glucose, and 3 mM CaCl 2 ). Before use, all solutions were filtered through a 0.8-m filter (Millipore Corporation, Bedford, MA) to remove any particulate contaminants. The perfusion fluid was gassed with 95% oxygen and 5% carbon dioxide (pH 7.3-7.5 at 37°C). An elastic water-filled latex balloon (no. 4; Hugo Sachs Electronik, Hugstetten, Germany) was inserted into the left ventricle through the mitral valve and connected to a pressure transducer, the output of which was connected to a physiograph. The filling pressure was individually adjusted to 12 to 18 mm Hg (1.6 -2.5 kPa) to achieve a maximal contractile performance. A TA 240 recorder (Gould, Cleveland, OH) was used to measure heart rate and intraventricular pressures: left end diastolic ventricular pressure (LEDVP) and left systolic ventricular pressure. The left ventricular developed pressure (LVDP) was calculated from left systolic ventricular pressure Ϫ LEDVP and rate-pressure product (RPP) was from the product of LVDP and heart rate. Coronary flow was measured by the timed collection of the effluent.
Perfusion Protocols. Twelve groups of hearts were subjected to different ischemia-reperfusion protocols at 37°C (Fig. 1) . After a stabilization phase of 15 min, isolated hearts were perfused aerobically for 15 min (preischemic control period). Global normothermic ischemia was then induced by clamping aortic inflow for 30 min, during which a thermoregulated chamber maintained the heart temperature at 37°C. After ischemia, aortic inflow was resumed for 30 min (reperfusion period).
In a first series of experiments (PBN-free groups), hearts were infused with 100 M N G -nitro-D-arginine methyl ester (D-NAME; group 1a, n ϭ 7), 100 M L-NAME (group 2a, n ϭ 7), 3 mM D-arginine (group 3a, n ϭ 7), or 3 mM L-arginine (group 4a, n ϭ 7). The compounds were directly dissolved in the perfusion medium and administrated 10 min before ischemia and throughout reperfusion period.
In a second series of experiments (PBN-treated groups), isolated hearts were administrated the same compounds under the same conditions (100 M D-NAME, group 1b, n ϭ 14; 100 M L-NAME, group 2b, n ϭ 15; 3 mM D-arginine, group 3b, n ϭ 6; and 3 mM L-arginine, group 4b, n ϭ 6). The amount of free radicals released was measured with spin trapping ESR as described previously (Vergely et al., 2001b) . The spin trap PBN (3 mM) was infused upstream of the coronary bed 5 min before the onset of ischemia and during the reperfusion period (15 min from the beginning and 5 min before the end of the reperfusion period). Five-microliter aliquots of coronary effluent samples were collected at different times before ischemia and during reperfusion (Fig. 1, arrows) , immediately extracted with 0.75 ml of N 2 -gassed ice-cold toluene, frozen, and kept into liquid nitrogen until ESR measurement.
ESR Spin Trapping. Toluene extracts were thawed and bubbled with N 2 for 20 s. ESR spectra were recorded at 293°K with an ESP 300E-X band spectrometer (Bruker, Wissenbourg, France) using a TM 110 cavity and an aqueous flat cell. The following parameters were selected for optimal detection of PBN spin adducts: microwave power, 20 mW; microwave frequency, 9.74 GHz; modulation amplitude, 1.6 G; modulation frequency, 100 kHz; gain, 1.6 to 3.2 ϫ 10 6 ; scan rate, 0.95 G s
Ϫ1
; time constant, 163.84 ms; and conversion time, 82 ms. The signal intensity, which is proportional to the concentration of spin adducts, was measured directly from the field scan and expressed as spin adduct concentration (nM) by double integration of the experimental spectra using 2,2,6,6 tetramethylpiperidine-N-oxyl nitroxide as an integration standard. The spin adduct release rate (pmol/min/g of heart) at each perfusion time was obtained by multiplying the adduct concentration by the respective coronary flow.
Determination of Oxygen Radical Absorbance Capacity. The potential antioxidant properties of D-arginine, L-arginine, D-NAME, and L-NAME were evaluated as oxygen radical absorbance capacity (ORAC) according to a modified method of Cao et al. (1993) . Briefly, the reaction mixture contained a final concentration of 3.75 ϫ 10 Ϫ8 M ␤-allophycocyanin in 75 mM phosphate buffer, pH 7.0, at 37°C in the presence or the absence of Trolox (1 M) or of the compounds (10 M-10 mM). The reaction was initiated by the introduction of 3 ϫ 10 Ϫ3 M 2,2Ј-azobis(2-amidinopropane)-4-hydrochloride and followed spectrophotometrically by the decrease in fluorescence at 598-nm excitation and 615-nm emission. Trolox was used as a reference antioxidant for calculating the ORAC values, with one ORAC unit defined as the net protection area provided by 1 M final concentration of Trolox.
Statistical Analysis. All data are presented as means Ϯ S.E.M. Statistical analysis was performed with a t test, determining differences between L-or D-compound-treated hearts, at each time of the perfusion protocol.
Results

Myocardial Functional Parameters during Experimental Ischemia-Reperfusion: PBN-Free Hearts
Coronary Flow. At the beginning of the preischemic perfusion period, the coronary flow of isolated perfused hearts ( Fig. 2) was stable around the value of 14 ml/min (16 ml/ min/g of heart tissue).
The administration of 100 M D-NAME ( Fig. 2A ), started 5 min thereafter, did not significantly influence the evolution of coronary flow, despite a small and progressive increase (12%). Conversely, when 100 M L-NAME was infused upstream of the coronary bed, the increase of vascular resistances led to a significant decrease in coronary flow: just before the induction of ischemia, the coronary flow of L-NAME-treated hearts was 46% lower than the control group treated with D-NAME. After 30 min of no-flow ischemia, reperfusion allowed only a partial recovery of coronary flow, reaching only 50% of its preischemic value. The administration of L-NAME during reperfusion led to an even lower postischemic coronary flow, with significant intergroup differences observed from the beginning of reperfusion.
The administration of 3 mM D-or L-arginine (Fig. 2B ) during the preischemic perfusion period slightly decreased (11%) the level of coronary flow. During postischemic reperfusion, the coronary flow was dramatically impaired and recovered to ϳ25% of its initial value. No differences in the evolution of coronary flow were seen between these two groups. Fig. 1 . Perfusion protocols of PBNfree or PBN-treated groups of isolated rat hearts. Drug perfusion was started 10 min before the induction of ischemia and continued throughout 30 min of reperfusion. PBN (3 mM) was perfused as indicated under Materials and Methods. Arrows (1) indicate time for coronary sample collection.
Fig. 2. Evolution of coronary flow of isolated rat hearts treated with 100
M NAME (A) or 3 mM arginine (B), before, during, and after 30 min of global total ischemia. The time for the administration of compounds is shown with the arrow. Results are presented as means Ϯ S.E.M. E, 100 M D-NAME-treated hearts (n ϭ 7); F, 100 M L-NAME-treated hearts (n ϭ 7); Ⅺ, 3 mM D-arginine-treated hearts (n ϭ 7); f, 3 mM L-argininetreated hearts (n ϭ 7). Significantly different from the D-analog group: ૺ, P Ͻ 0.05; ૺૺ, P Ͻ 0.01; ૺૺૺ, P Ͻ 0.001.
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The induction of ischemia was rapidly followed by the cessation of myocardial contractions and by a gradual increase in intraventricular pressure, representative of the phenomenon of ischemic contracture. After 20 min of ischemia, the intraventricular pressure reached a peak value close to 80 mm Hg and then decreased slowly. The pressure inside the left ventricle was shown to be statistically lower at the end of ischemia for hearts administered with 100 M D-NAME.
Upon the relief from 30 min of global ischemia, LEDVP increased rapidly and reached a maximum 3 min after the onset of reperfusion, a feature characteristic of postischemic contracture. This peak of LEDVP was between 95 and 100 mm Hg for NAME-treated hearts and between 108 and 120 mm Hg for arginine-treated hearts, with a significantly higher peak level for L-arginine. Then LDVP decreased slowly but remained at a high level during the whole reperfusion period. No differences in the recovery of LEDVP were observed between L-or D-groups. However, LEDVP was at least 20 mm Hg lower at the end of the reperfusion period for hearts treated with 100 M D-or L-NAME than with D-or L-arginine.
Rate-Pressure Product. RPP corresponds to the product of LVDP (left end systolic ventricular pressure Ϫ LEDVP) and heart rate and is usually considered as a good index of myocardial contractile efficiency (Fig. 4) . The RPP of isolated perfused rat hearts was initially close to 40 ϫ 10 3 beats ⅐ mm Hg/min.
The administration of 100 M L-NAME induced a progressive 30% decrease of RPP (P Ͻ 0.05), consecutive to the impairment of LVDP without changes in heart rate. Conversely, 3 mM L-arginine did not modify the evolution of RPP, compared with D-arginine.
During ischemia, contractions ceased, and LVDP and RPP were reduced to zero. With reperfusion, RPP was only slightly restored and remained at a low level at the end of the reperfusion period. The final RPP of NAME-or argininetreated hearts corresponded to only 30 and 10% of its initial value, respectively, without intergroup differences. Compared with the preischemic level of RPP, the recovery of hearts infused with D-NAME was 29 Ϯ 11 versus 40 Ϯ 11% with L-NAME.
Rhythm Disturbances. Rhythm abnormalities (Fig. 5 ) are frequently observed after 30 min of a global normothermic ischemia and are mostly represented by ventricular tachycardia and fibrillation. The average duration of these rhythm disturbances was not modified by the treatment with the active compound.
Myocardial Functional Parameters of Control Hearts during Experimental Ischemia-Reperfusion. The evolution of functional parameters of isolated rat hearts treated neither with any of the arginine analogs nor with PBN is presented as an indication in Table 1 . The recovery of coronary flow LVDP and RPP was 43 Ϯ 4, 31 Ϯ 14, and 21 Ϯ 14%, respectively. Because this control group was not processed at the same moment as the arginine analogs, they are not directly comparable.
Myocardial Functional Parameters and Spin Adduct Release Rate of PBN-Treated Hearts during Experimental Ischemia-Reperfusion
Functional Parameters. The evolution of functional parameters of PBN-treated hearts is presented in Table 2 . As already observed without PBN, L-NAME perfusion induced a significant diminution of coronary flow, LVDP, and RPP under preischemic control perfusion conditions. The administration of 3 mM L-arginine before ischemia was not responsible for any modifications of functional parameters, compared with D-arginine. At the end of reperfusion, myocardial parameters were not different between hearts treated with D-or L-NAME. For the hearts that were perfused in the presence of 3 mM D-or L-arginine, all parameters were comparable at the end of the postischemic period, except for LEDVP, which was significantly higher in the L-arginine group.
ESR Spin Trapping. Experiments performed with ESR on coronary effluents showed the presence of a sextuplet signal (a N ϭ 13.5 G; a H ϭ 2.1 G; g ϭ 2.012) with coupling constants that could be attributed to alkyl/alkoxyl spin adducts, but also of a triplet (a N ϭ 7.9 G; g ϭ 2.013) that could be attributed to an oxidation product of PBN, benzoyl-tertbutyl nitroxide (Fig. 6) . The concentration of these free radical species in the coronary effluent was evaluated, and the spin adduct release rate was calculated by taking into ac- Fig. 3 . Evolution of LEDVP of isolated rat hearts treated with 100 M NAME (A) or 3 mM arginine (B), before during and after 30 min of global total ischemia. The time for the administration of compounds is shown with the arrow. Results are presented as means Ϯ S.E.M. E, 100 M D-NAME-treated hearts (n ϭ 7); F, 100 M L-NAME-treated hearts (n ϭ 7); Ⅺ, 3 mM D-arginine-treated hearts (n ϭ 7); and f, 3 mM L-argininetreated hearts (n ϭ 7). Significantly different from the D-analog group: ૺ, P Ͻ 0.05. (Fig. 7) . During normoxic preischemic perfusion, a low spin adduct release rate was observed in coronary effluents, which was larger in the groups treated with D-or L-NAME. After reperfusion of the heart, a large release of alkyl/alkoxyl species occurred with spin adduct release rate reaching 4 times its preischemic level and remaining at a high level during 30 min of reperfusion. However, the treatment with the active (L-) or the inactive (D-) compound did not modify the release of spin adducts, before and after the induction of ischemia.
Antioxidant Activity of Compounds. The antioxidant capacity of D-and L-NAME and of D-and L-arginine was evaluated as their ability to protect a fluorescent protein (allophycocyanin) toward alkyl/alkoxyl radical-induced oxidation (Fig. 8) . Antioxidant properties were observed only with D-or L-NAME at the highest concentration (10 mM), with ORAC values reaching 0.91 Ϯ 0.07 and 1.43 Ϯ 0.13, respectively.
Discussion
NOS Modulation and Myocardial Function during
an Ischemia-Reperfusion Sequence. During ischemia and reperfusion ⅐ NO may have dual effects, beneficial in preserving endothelial function, preventing leukocyte adhesion, and promoting vasodilation, although harmful because Fig. 4 . Evolution of RPP (LVDP ϫ heart rate) of isolated rat hearts treated with 100 M NAME (A) or 3 mM arginine (B) before, during, and after 30 min of global total ischemia. The time for the administration of compounds is shown with the arrow. Results are presented as means Ϯ S.E.M. E, 100 M D-NAME-treated hearts (n ϭ 7); F, 100 M L-NAMEtreated hearts (n ϭ 7); Ⅺ, 3 mM Darginine-treated hearts (n ϭ 7); and f, 3 mM L-arginine-treated hearts (n ϭ 7). Significantly different from the D-analog group: ૺ, P Ͻ 0.05. 
TABLE 1
Evolution of myocardial functional parameters of a control group treated neither with NAME nor arginine nor PBN Data are presented as means Ϯ S.E.M. and correspond to the initial preischemic values (t ϭ 0), the values taken just before the induction of ischemia (t ϭ 14 min) and at the end of the reperfusion period (t ϭ 75 min). . to generate ONOO Ϫ . Peroxynitrite irreversibly inhibits both contractility and respiration, in contrast to the reversible effect of ⅐ NO (Radi et al., 1994; Xie et al., 1998) , which may represent an aggravating factor for the development of postischemic cellular injury. The balance between beneficial and deleterious effects of ⅐ NO is of key importance with respect to its pathophysiological role as a modulator of cardiac function.
The 100 M L-NAME infusion induced a rapid 46% decrease of coronary flow compared with D-NAME infusion. This increase in coronary vascular resistance can be directly attributed to the inhibition of NOS activity and the subsequent impairment of ⅐ NO-induced vasorelaxation, as was described previously in a similar model (Pabla and Curtis, 1995) . During L-NAME administration, the progressive decrease in RPP might be related to the impairment of oxygen and substrate supplies due to vasoconstriction. During postischemic reperfusion, coronary flow of L-NAME-treated hearts was still lower than the D-NAME group, but when the data were expressed as recovery of preischemic values, L-NAME groups showed higher coronary flow recovery than D-NAME (64 Ϯ 4 versus 51 Ϯ 3%, respectively). The evolution of contractility was not different between L-or D-NAMEtreated hearts during reperfusion, but the recovery of preischemic RPP was slightly higher for the L-NAME (40 Ϯ 11%) than for the D-NAME groups (29 Ϯ 11%). Various competitive inhibitors of NOS have been shown to reduce reperfusion injury in various settings (Depré et al., 1995; Naseem et al., 1995; Zweier et al., 1995; Wang and Zweier, 1996; du Toit et al., 1998; Zhang et al., 2001) . In contrast to the above-mentioned studies, some experiments reported that NOS antagonists can enhance postischemic myocardial injury (Brunner et al., 1997; du Toit et al., 1998) . The differences may be due to the experimental models, but also to the concentration of NOS antagonists, because nonvasoactive concentrations seem to protect the heart against postischemic injury (Depré   TABLE 2 Evolution of myocardial functional parameters of NAME (100 M)-or arginine (3 mM)-treated hearts for the groups receiving PBN (3 mM) as a spin trap Data are presented as means Ϯ S.E.M. and correspond to the initial preischemic values (t ϭ 0), the values taken just before the induction of ischemia (t ϭ 14 min) and at the end of the reperfusion period (t ϭ 75 min). D-NAME 100 M n ϭ 14 122.9 Ϯ 2.0 138.9 Ϯ 6.0 29.5 Ϯ 6.8 20 Ϯ 4 L-NAME 100 M n ϭ 15 127.5 Ϯ 4.9 107.9 Ϯ 9.2* 32.6 Ϯ 7.2 38 Ϯ 9 D-arginine 3 mM n ϭ 6 124.2 Ϯ 5.6 114.3 Ϯ 13.0 23.5 Ϯ 5.7 22 Ϯ 7 L-arginine 3 mM n ϭ 6 132.8 Ϯ 5.9 123.7 Ϯ 8.3 11.2 Ϯ 3.8 9 Ϯ 3 Heart rate (beats/min) D-NAME 100 M n ϭ 14 329.3 Ϯ 5.69 283.8 Ϯ 9.1 221.5 Ϯ 8.8 L-NAME 100 M n ϭ 15 326.7 Ϯ 7.4 258.7 Ϯ 10.9 196.9 Ϯ 13.9 D-arginine 3 mM n ϭ 6 323. du Toit et al., 1998) , whereas concentrations above 100 M would be detrimental. Moreover, when using vasoactive concentrations of NOS inhibitors, the result is considered as beneficial in terms of postischemic recovery (Zweier et al., 1995; Wang and Zweier, 1996) , or deleterious when expressed in net values (Brunner et al., 1997; du Toit et al., 1998) , as was experienced in our study. Therefore, because L-NAME treatment does not modify the duration of postischemic rhythm disturbances, we propose that the administration of 100 M L-NAME before 30 min of global ischemia and throughout reperfusion does not afford protection to the heart against postischemic injury. Under our experimental conditions, it was not possible to determine differences in cardiac function between D-or Larginine-treated hearts, despite a slight increase in postischemic peak LEDVP and a decrease in heart rate. Many authors have described beneficial effects of L-arginine treatment on the recovery of myocardial function during reperfusion (Engelman et al., 1996; Brunner et al., 1997; Wang et al., 1997; Mizuno et al., 1998; Padilla et al., 2000) , whereas others have shown a harmful effect of L-arginine administration (Takeuchi et al., 1995; Mori et al., 1998) . These discrepancies can be attributed to different experimental models but also to the critical timing of this amino acid administration. In fact, L-arginine seems even more powerful as a pretreatment (Engelman et al., 1996; Wang et al., 1997; Mizuno et al., 1998) , and sometimes deleterious during reperfusion (Takeuchi et al., 1995; Engelman et al., 1996) . Therefore, the absence of functional parameters' variations between D-or L-arginine observed under our experimental conditions might be the addition of both beneficial and detrimental effects of L-arginine administration.
The effects of NAME or arginine administration were not compared in our study because the experiments were not processed exactly at the same moment. Therefore, in our experimental conditions, the addition of either the substrate or a competitive inhibitor of NOS did not modify significantly the ability of the heart to recover from the ischemic insult.
NOS Modulation and Postischemic Oxidative Stress. Using the technique of electron spin resonance associated with PBN spin trapping, we have investigated the effect of modulating NOS activity on the release of radical species. This method allows direct identification of secondary free radicals released by the heart during postischemic reperfusion (Bolli et al., 1988; Blasig et al., 1994) . It is noteworthy that PBN in itself can modify the evolution of cardiovascular parameters (Vergely et al., 2001b) , but this spin trap is a valuable tool when investigating the release of free radical species in biological systems. In the present work, our first observation was that the preischemic period was associated with the presence, at a low level, of alkyl/alkoxyl radicals trapped in coronary effluents. After 30 min of global ischemia, a 3-to 5-fold increase in the initial spin adduct release rate was observed, which was maintained at a high level throughout reperfusion. Alkyl/alkoxyl radicals are secondary free radicals, formed by the reaction of primary species such as O 2 . or hydroxyl radical (HO ⅐ ) on different molecules in their environment. The presence of such secondary species in the coronary effluent of perfused hearts is likely to originate not only from the cell components exposed to an oxidative stress but also from the oxidation of perfusion buffer constituents (Kalyanaraman et al., 1994) . The postischemic free radical release kinetics is consistent with a previous study (Vergely et al., 2001b) and shows almost the same pattern among arginine-or NAME-treated hearts. However, preischemic and postischemic levels are lower in arginine treatment. The same variability in preischemic spin adduct signals have been observed for other protocols in our laboratory (Vergely et al., 2001a) and might originate from using different batches of high-purity PBN. Because the production of secondary radical adducts is influenced not only by the level of oxidative stress but also by the Fig. 7 . Free radical release rate before and after 30 min of global total ischemia for 100 M NAME-(A) or 3 mM arginine (B)-treated hearts. Results are presented as means Ϯ S.E.M. E, 100 M D-NAME-treated hearts (n ϭ 14); F, 100 M L-NAME-treated hearts (n ϭ 15); Ⅺ, 3 mM D-argininetreated hearts (n ϭ 6); and f, 3 mM L-arginine-treated hearts (n ϭ 6). presence of other trapping molecules in the environment, it is possible that a 3 mM concentration of arginine is an appropriate tool to prevent free radicals from reacting either with cell constituents or with the spin trap. Indeed, antioxidant properties of D-and L-arginine (Rehman et al., 1997; Walner et al., 2001 ) and of D-and L-NAME (Rehman et al., 1997) have been described on HO ⅐ (Rehman et al., 1997) or against lipoprotein oxidation (Walner et al., 2001) . However, by using the ORAC test, we observed that 100 M D-and L-arginine or 3 mM D-or L-NAME afforded low antioxidant properties against an alkyl/alkoxyl-generating system.
Another important observation from our work is that the spin adduct release rate during reperfusion is not modified by the treatment with the active enantiomers of arginine or NAME. Therefore, the positive or negative modulation of NOS activity does not seem to influence the level of postischemic oxidative stress. Several authors have provided evidence that uncoupled electron transfer can occur in NOS, leading to the production of superoxide. In physiological conditions, cells probably maintain sufficient levels of L-arginine for NOS to catalyze NO synthesis, because L-arginine is found in mammalian cells at concentrations by far exceeding the K M values of these enzymes. However, in conditions such as ischemia and reperfusion, where a leak in amino acids is observed (Brunner et al., 1997; Song et al., 1998) , the availability of L-arginine and tetrahydrobiopterin could be impaired and would participate in NOS-induced generation of O 2 . . Therefore, the administration of either L-arginine or L-NAME should reduce uncoupled generation of reactive oxygen species by NOS. On the other hand, as a trap for O 2 . , ⅐ NO produced in cardiac cells during reperfusion may preserve the tissues from reactive oxygen species-driven reactions, and the administration of L-arginine would lower, whereas L-NAME would enhance postischemic oxidative stress. However, in our experimental conditions, no modification in the level of postischemic release of secondary free radicals was observed when the hearts were perfused in the presence of 3 mM L-arginine or 100 M L-NAME in comparison with the inactive D-enantiomer treatment. Because there was no additional benefit in terms of postischemic insult, we support the hypothesis that NOS uncoupling and NOS-driven reactions might not play a major role in the etiology of the oxidative stress that occurs after 30 min of global ischemia. This assertion cannot be extrapolated to in vivo conditions where the presence of circulating immunoinflammatory cells are a supplementary source of nitric oxide and of oxidative stress.
In conclusion, using either L-NAME as a competitive inhibitor or L-arginine as a substrate of NOS, in comparison with specific enantiomers, our study failed to demonstrate either a positive or negative role of NOS modulation during ischemia and reperfusion, not only upon functional recovery but also on postischemic oxidative stress. These results indicate that, in our experimental conditions, cardiac ⅐ NO synthases might not be major components implicated in the oxidative burst that follows a global myocardial ischemia.
